Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

PTC acquires Censa: diversifying into metabolic disease

New Jersey-based PTC Therapeutics has acquired another rare disease company, Censa Pharmaceuticals, for $10m in cash upfront. Censa has developed a novel drug for PKU, and other rare diseases linked with the BH4 pathway, thereby allowing PTC to diversify into metabolic diseases. How does this deal fit in with PTC’s business strategy?

Close
Close
Close

Go Top